GFM
CYTK icon

GF Fund Management’s Cytokinetics CYTK Stock Holding History

GF Fund Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Sell
2,608
-138
-5% -$9.91K ﹤0.01% 266
2026
Q1 		$181K Buy
2,746
+344
+14% +$21.9K ﹤0.01% 291
2025
Q4 		$153K Sell
2,402
-172
-7% -$10.7K ﹤0.01% 314
2025
Q3 		$141K Sell
2,574
-447
-15% -$18.4K ﹤0.01% 315
2025
Q2 		$99.8K Hold
3,021
– – ﹤0.01% 366
2025
Q1 		$121K Buy
3,021
+543
+22% +$25K ﹤0.01% 350
2024
Q4 		$117K Buy
+2,478
New +$129K ﹤0.01% 319

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GF Fund Management's CYTK Position: Q2 2026 in Review

GF Fund Management reduced its Cytokinetics (CYTK) stake by 5% in Q2 2026, selling an estimated $9.91K and leaving 2,608 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #266.

GF Fund Management first reported a position in CYTK in Q4 2024 and has held it in 7 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • GF Fund Management held 2,608 shares of Cytokinetics worth $222K as of Q2 2026.
  • GF Fund Management sold 138 Cytokinetics shares in Q2 2026, an estimated $9.91K.
  • Cytokinetics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #266 holding.
  • GF Fund Management first reported a position in Cytokinetics in Q4 2024 and has held it in 7 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.